Home > Focus Areas > DLBCL Connect > Post
4yr
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33683917/
doi: 10.1200/JCO.20.03433. Online ahead of print. 1 The University of Texas MD Anderson Cancer Center, Houston, TX. 2 Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland. 3 Levine Cancer Institute, Atrium Health, Charlotte, NC. 4 Onco-Hematology Division, European Institute of Oncology IRCCS, Milan, Italy. 5 Department of Health Sciences, University of Milan, Milan, Italy.
-
Mark Fesler4yrIn cross trial comparison this pi3k inhibitor appears to have less toxicity than its predecessors ...will be nice to see if randomized comparative data emerged to prove this